Novavax slid Thursday in its worst session in more than four months after laying out plans to refinance $225 million of debt, ...

As a summer COVID-19 surge hits Michigan, unanswered questions abound about eligibility, insurance coverage and when new ...

If you’re eyeing Novavax (NVAX) today, you’re not alone, and the reason is clear. Investors are buzzing after the company announced a refinancing deal that pushes out most of its convertible debt from ...

Pfizer's JN.1 vaccine has been the only option available to Australians since the start of the year. Here's what happened to ...

Bank of America cut its rating on Novavax (NASDAQ:NVAX) to Underperform from Neutral and lowered its price objective to $7 from $9, saying recent gains in the shares have overrun a still uncertain ...

"Novavax's authorization today means people will now have the choice of a protein-based non-MRNA option to help protect themselves against COVID-19, which is now the fourth leading cause of death ...

The American College of Obstetricians and Gynecologists on Friday said it continues to recommend the use of COVID-19 vaccines ...

Novavax’s UK trial, with more than 15,000 participants ages 18 to 84, found that the vaccine had an efficacy of 96.4% against mild, moderate and severe disease caused by the original coronavirus ...

The first results from a large efficacy study of a new kind of COVID-19 vaccine are now out, and they are good. Very good. According to Novavax, the vaccine's manufacturer, it had a 100% efficacy ...

Novavax COVID vaccine shows strong efficacy The biotechnology company announced Monday that its stage three clinical trial showed overall efficacy of 90.4% against COVID-19.

Novavax’s latecomer Covid-19 vaccine gets U.S. authorization. The vaccine was authorized as a primary immunization series for adults, rather than a booster, which may limit its market at first.